In the current study, we examined these bone seeking MMP inhibitors (BMMPIs) for their in vivo efficacy in the setting of multiple myeloma using independent clinically relevant models of the disease (5TGM1 and U266), and addressed as proof of principle whether individual MMP activity, in this case MMP-2, could be selectively inhibited in skeletal tissue. The gene discussed is MMP2; the disease is plasma cell myeloma.